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Abstract Purpose: The clinical
use of vasoactive drugs is not only
intended to improve systemic hemo-
dynamic variables, but ultimately to
attenuate derangements in organ per-
fusion and oxygenation during shock.
This review aims (1) to discuss basic
physiology with respect to manipu-
lating vascular tone and its effect on
the microcirculation, and (2) to pro-
vide an overview of available clinical
data on the relation between vasoac-
tive drugs and organ perfusion, with
speciﬁc attention paid to recent
developments that have enabled
direct in vivo observation of the
microcirculation and concepts that
have originated from it. Methods:
A MedLine search was conducted for
clinical articles in the English lan-
guage over the last 15 years pertainig
to shock, sepsis, organ failure, or
critically ill patients in combination
with vasoactive drugs and speciﬁc
variables of organ perfusion/oxygen-
ation (e.g., tonometry, indocyanine
clearance, laser Doppler, and side-
stream dark ﬁeld imaging).
Results: Eighty original papers
evaluating the speciﬁc relationship
between organ perfusion/oxygenation
and the use of vasoactive drugs were
identiﬁed and are discussed in light of
physiological theory of vasomotor
tone. Conclusions: Solid clinical
data in support of the idea that
increasing blood pressure in shock
improves microcirculatory perfusion/
oxygenation seem to be lacking, and
such a concept might not be in line
with physiological theory of micro-
circulation as a low-pressure vascular
compartment. In septic shock no
beneﬁcial effect on microcirculatory
perfusion above a mean arterial
pressure of 65 mmHg has been
reported, but a wide range in inter-
individual effect seems to exist.
Whether improvement of microcir-
culatory perfusion is associated with
better patient outcome remains to be
elucidated.
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Introduction
Although shock is deﬁned in terms of a critically low
blood pressure, a more generally accepted and physiol-
ogy-based deﬁnition of shock is: the inability of the
circulation to sustain the cellular respiration needed to
maintain normal organ function [1]. This controversy in
deﬁnition reﬂects an underlying dilemma with profound
effects at bedside. Although intensivists are aware of the
physiology-based mechanisms of shock, they have to rely
on surrogate global upstream (e.g., blood pressure) and/or
downstream (e.g., SvO2) hemodynamic variables to
Intensive Care Med (2010) 36:2004–2018
DOI 10.1007/s00134-010-1970-x REVIEWdiagnose ‘inadequate’ organ perfusion and guide therapy.
Attempts to integrate regional indicators such as intestinal
CO2, lactate and indocyanine green (ICG) clearance,
which have all been associated with prognosis, have had
limited success.
Apart from these general limitations, it becomes clear
that in distributive shock shunting in the microcirculation
is an intrinsic complexity. Although theoretically the
concept of shunting has been well known for many dec-
ades [2], new technologies have elucidated the role of
‘microcirculatory weak units.’ In a model of ischemia
reperfusion, a speckled pattern of NADH ﬂuorescence
and pO2 emerged after re-oxygenation, indicating an
inhomogeneous distribution of cells more vulnerable to
ischemic insults than others. Microsphere embolization
determined these so-called ‘weak units’ at the capillary
level [3]. Provided upstream oxygen delivery is adequate,
shunted parts of the microcirculation remain hypoxic in
the presence of well-maintained venous pO2, explaining
the persistence of elevated lactate and regional pCO2
levels [4] not sensed by the downstream variables such
as SvO2 [5]. The net systemic result is an inability
to increase tissue oxygen uptake, despite efforts to
‘(supra)normalize’ oxygen delivery, but whether this
reﬂects a true extraction deﬁcit as result of a preceded
cellular metabolic shutdown or a potentially correctable
state of inhomogeneous hypo perfusion remains to be
established [6]. Because of the introduction of direct in
vivo observation of the microcirculation [7], heterogene-
ity of blood ﬂow has now become a key feature of
distributive shock. It has not only been reported within
the microcirculation [8], but also between different
organs, within different regions of one organ, in response
to therapeutic interventions and in a time-dependent way
[4, 9], all challenging the simplicity of systemic hemo-
dynamic monitoring under such conditions.
At ﬁrst evaluation, these observations seem to add
more data to the already dazzling complexity of treatment
modalities in the critically ill. However, these new insights
have established two main ﬁndings: (1) the independent
perfusion behavior of the microcirculation in relation to
classically measured systemic hemodynamic variables,
albeit within certain absolute limits of minimal perfusion
pressure [8], and (2) persistence of microcirculatory
alterations are associated with morbidity and mortality
under various conditions, irrespective of correction of
systemic hemodynamics [10, 11]. The issue to be resolved
is whether correction of microcirculatory distributive
alterations will improve organ function and morbidity. In
order to explore this exiting concept, it is not sufﬁcient to
‘simply’ ﬁnd novel therapeutic approaches that speciﬁ-
cally aim to reopen the microcirculation directly. We also
have to be prepared to (re)evaluate our current strategies at
the bedside in the light of its potential effects from the
perspective of the microcirculation and relate it to organ
function and outcome.
Administration of vasoactive compounds and ﬂuid
therapy are the cornerstone of hemodynamic management
of critically ill patients. In this paper we will review
reported effects of vasoactive substances on microcircu-
latory perfusion and tissue oxygenation in shock. These
compounds have been advocated to improve systemic
perfusion pressure and oxygen delivery, with subsequent
improvement of tissue perfusion and oxygen uptake [12].
But do they behave the way we expect them to do? Since
shock is a syndrome rather than a well-deﬁned patho-
physiologic entity, disease itself as well as treatment
might contribute to the clinical picture [13]. An appreci-
ation of basic physiology with respect to manipulating
vascular tone and its effect on the microcirculation is
followed by a systematic review of the literature. We will
focus our review on recent clinical research that includes
microcirculatory effects of three classes of vasoactive
substances: vasopressors, inotropes and vasodilators, and
follow the suggested classiﬁcation of shock etiology [2].
Preclinical studies will only be discussed in so far as they
pertain to the clinical studies.
Materials and methods
In MedLine the following search strategy was per-
formed. Article titles containing shock or sepsis or septic
or organ failure or critically ill in combination with
vasopressor or vasoactive or inotrope or inotropic or
vasodilator or several speciﬁc vasoactive drugs [e.g.,
(nor)adrenaline/(nor)epinephrine, vasopressin, dopamine,
dobutamine, nitroglycerin] were selected. The search
was restricted to clinical studies in the English language,
published over the last 15 years, where indicators of
microcirculatory or regional perfusion were speciﬁcally
mentioned, or in case the effect was evaluated with aid
of speciﬁc microcirculatory or regional techniques [e.g.,
tonometry/capnography, ICG, orthogonal polarization
spectral (OPS)/side-stream dark ﬁeld (SDF) imaging,
spectrophotometry (Table 1)].
Results
Physiology
Microcirculatory perfusion pressure is the net result of
precapillary inﬂow pressure minus venular outﬂow pres-
sure. Most of the pressure drop occurs upstream in small
arterioles (resistance vessels) as the principal site of
active diameter changes to achieve regulation of blood
ﬂow. Mean capillary pressure is therefore much closer to
venous pressure than to arterial pressure, which is rele-
vant for the maintenance of tissue ﬂuid balance [14].
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2006Under normal conditions sympathic vasoconstriction is
reduced in case of venular hypoxia. This signal is for-
warded upstream electrophysiologically via endothelial
cells connected by gap junctions proximal to arterioles
causing upstream dilatation. This process is regulated per
microcirculatory unit arising from the respective arteriole
feed vessels [15]. It is proposed that the ‘sensor’ for
detecting changes in ambient pO2 is located downstream
and acts by release of nitric oxide (NO) in the venules
[16]. In this respect additional exogenous precapillary and
postcapillary vasoconstriction by means of a vasopressive
drug results in a reduced net perfusion pressure over the
microcirculation [17], despite increment of systemic
blood pressure (Fig. 1). At the same time shunting may
disrupt the normal venular signaling process for vasodi-
latation to prevent local hypoxia. Indeed, in ischemia/
reperfusion local hypoxia persists in ‘microcirculatory
weak units’ after restoration of oxygen delivery in a
speckled pattern that appears to be determined at the
capillary level, but not at the arteriolar level [3].
Apart from interference in the complex regulation of
tissue perfusion, vasoactive drugs may also inﬂuence the
homeostasis of tissue oxygenation. Tissue oxygenation is
not only dependent on convective properties of red blood
cells (ﬂow), but is also determined by diffusion. Given the
gas-speciﬁc characteristics, oxygen diffusion is related to
the pressure gradient and inversely related to the distance
between the capillary and the cell (Fig. 2). Closing
Fig. 1 Left panel arteriolar vasodilation increases the opening
pressure of the microcirculation as result of a decrease in pressure
drop prior to the microvascular compartment. Right panel
combined arteriolar and venular increment of vascular tone reduces
the net driving pressure over the microvascular compartment (from
[17] by permission)
Fig. 2 Convective transport of
oxygen through the capillaries
depends on red blood cell
velocity, capillary hematocrit
and oxygen saturation. Oxygen
transport from the capillary to
the cell via diffusion is
inversely related to the
diffusion distance (D1 and D2)
according to Fick’s law
2007capillaries in order to maintain perfusion pressure
increases diffusion distance and vice versa. Under resting
conditions capillaries constantly perform changes in cal-
iber in order to serve both purposes [15].
A third factor that inﬂuences microcirculatory oxygen
delivery is capillary hematocrit. Mechanical interaction
between red blood cells and vessel walls induces the
formation of a plasma layer adjacent to the wall and
increases hematocrit in the center. Since blood ﬂow-
velocity distribution has a parabolic shape, from zero next
to the wall to a maximum at the center, the average red
cell velocity is higher than overall blood velocity. As a
consequence, red cell transit time is reduced. This results
in dynamic lowering of the capillary hematocrit in com-
parison to the entering and discharge hematocrit, and
is known as the Fahraeus effect [18]. Additional to
this effect, capillary hematocrit is also determined by a
phenomenon, originally described by Krogh as ‘plasma
skimming’ [19]. At the diverging branches of the capil-
lary network, distribution of red cells is related to the
diameter of the daughter vessels (Fig. 3). During in vitro
experiments at a systemic hematocrit of 50%, capillary
hematocrit ranged from 6.8% during vasoconstriction to
38% under vasodilatation [20], with profound implica-
tions on capillary oxygen transport. From the perspective
of microcirculation, the dilemma of the use of vasopres-
sors to enhance organ perfusion and oxygenation cannot
be better expressed than in the original observations
by Krogh: ‘This plasma skimming is usually very pro-
nounced when adrenaline is applied in small drops to
muscle arteries of which all branches, even the smallest,
react and show a contraction, which in a short time may
become complete. The portion of the muscle supplied by
the contracting artery becomes blanched and the capil-
laries often disappear completely from view, while
application of adrenaline to capillaries and venules alone
shows that these vessels do not react visibly to the sub-
stance’ [19].
Despite abundant experimental data, little is known
about human in vivo alterations of vasomotor tone during
shock. Direct in vivo observations of the microcirculation
in animal endotoxemia demonstrated loss of arterial
vasomotion. Interestingly, not all vessels were affected at
once, but areas with stagnant blood ﬂow were observed
next to areas with brisk ﬂow [21]. In humans, topical
endotoxin exposure produced acute venous hyporespon-
siveness to NE or sympathic nervous system activation.
This was inhibited by glucocorticoids, butnot mitigated by
NO synthase- or cyclo-oxygenase inhibitors, suggesting
other mediators than NO or prostanoids contribute to the
overall vascular response to endotoxin [22]. Systemic LPS
injection in healthy volunteers blunted the vascular baro-
reﬂex response against nitroprusside-induced hypotension
and caused complete uncoupling of the cardiac baroreﬂex
from prevailing blood pressure [23]. At present, no direct
observations of the microcirculation, other than in tongue
or skin, are available from human endotoxemia models.
Human studies
Vasopressors
Norepinephrine (a and b-adrenergic, Table 2) is the most
commonly advocated vasopressive drug in septic shock to
maintain mean arterial pressure (MAP) at a minimum
level of 65 mmHg [12]. Although suggested, improve-
ment of outcome as a result of the use of NE has never
been established [24]. Recent studies, which included
direct in vivo observation of the microcirculation with
Sidestream Dark Field (SDF) imaging, have established
that in human sepsis further increment of MAP above
65 mmHg by means of NE does not improve sublingual
microcirculatory perfusion, intestinal pCO2 concentra-
tions or arterial lactate levels [25, 26]. This conﬁrmed
previous reports in which stepwise increases of MAP with
Fig. 3 Under experimental
conditions with a systemic
hematocrit (HA) of 50%,
capillary hematocrit (Hcap)
ranges from 6.8% under
vasoconstriction to 38% under
vasodilation. (From [20]b y
permission)
2008cumulating NE doses did not change arterial lactate levels,
skin capillary blood ﬂow, arterial-to-gastric pCO2 gradient
(pCO2 g-a), systemic oxygen uptake or renal function [27,
28]. However, substantial inter-individual differences
were observed, related to baseline values of microvascular
blood ﬂow [25]. Furthermore, these effects may be time
and situation dependent [29], and equal changes in MAP
may have different drug-related effects on organ perfusion
[30]. For renal function an optimal MAP of 75 mmHg in
sepsis has been suggested, but direct in vivo observations
of the renal microcirculation has not been performed [31].
These studies underline the concept that under conditions
of a minimal systemic perfusion pressure, an additional
rise in arterial pressure does not automatically improve
microcirculatory perfusion in distributive shock, in
accordance with physiological theory [17]. Clearly,
despite important efforts to compare mortality, systemic
and regional perfusion and cardiovascular side effects
between (combinations with) NE and other vasopressors,
these studies do not elucidate its individual effects on the
microcirculation or establish a critical minimum MAP
with respect to microcirculatory organ perfusion [32–35].
An observed relation between both hypotension and
mortality, as well as vasopressor load and mortality, may
be related to the event itself, but may also be a marker for
severity of illness [36, 37].
In cardiogenic shock, inotropic agents, but not vaso-
pressors, are advocated [38, 39]. Intra-aortic balloon
counter pulsation instantly improved sublingual microcir-
culatorybloodﬂowincardiogenicshock,butadditionalNE
Table 2 Adrenergic vasopressors (summary of effects in human studies on microvascular perfusion, oxygenation and organ function)
Study [ref] Vasopressor Setting Technique(s) Effects Remarks
[11, 25] Norepinephrine Septic shock,
n = 20, n = 20
SDF-imaging,
tonometry, laser-
Doppler
No change in sublingual
microvascular blood
ﬂow, lactate or pCO2 g-a
Stepwise increase MAP
from 65 to 85 mmHg,
individual effect
baseline-dependent
[27] Norepinephrine Septic shock, n = 10 Laser-Doppler,
tonometry
No difference in skin
capillary blood ﬂow,
pCO2g - a , lactate or
urine output
Stepwise increase MAP
from 65 to 85 mmHg
[28] Norepinephrine Septic shock, n = 28 Creatinine clearance No difference in lactate,
urine output or
creatinine clearance
Comparison between
MAP 65 and 85 mmHg
[31] Norepinephrine Septic shock, n = 11 Doppler
ultrasonography,
creatinine clearance
Decrease in renal resistive
index, increase in urine
output, no change in
creatinine clearance
Effect between MAP 65
and 75, no further
change at 85 mmHg
[42] Epinephrine Septic shock, n = 8 Tonometry, hepatic
vein lactate, ICG
clearance
Decrease in mucosal pH
and splanchnic blood
ﬂow, increase in hepatic
vein lactate
Cross-over, in addition to
norepinephrine plus
dobutamine
[34] Phenylephrine Septic shock, n = 32 Tonometry, ICG
clearance
No change in splancnic
blood ﬂow, pCO2 g-a,
lactate, urine output or
creatinine clearance
Increment MAP from 65
to 75 mmHg,
comparison between
norepinephrine and
phenylephrine
[44] Phenylephrine Septic shock, n = 15 Tonometry, ICG
clearance
Decrease in splanchnic
blood ﬂow, pCO2 g-a,
lactate or creatinine
clearance
Switching from
norepinephrine to
phenylephrine under
steady state MAP at
70 mmHg
[45] Phenylephrine Cardiopulmonary
bypass, n = 15
SDF-imaging, laser-
Doppler ﬂowmetry,
spectrophotometry
Decrease in sublingual
capillary blood ﬂow
together with an
increase in
microcirculatory
hemoglobin oxygen
saturation and overall
sublingual blood ﬂow,
suggesting shunt
Increment MAP from 47
to 68 mmHg under
steady state cardiac
output
[74] Dopamine
(high dose)
Septic shock, n = 20 Tonometry Decrease in gastric
mucosal pH
Increment MAP from B60
to C75 mmHg, under
norepinephrine
intestinal pH decreased
SDF Sidestream dark ﬁeld, pCO2 g-a arterial-to-gastric pCO2 gradient, MAP mean arterial pressure, ICG indocyanine green
2009dosage was inversely correlated with microcirculatory
blood ﬂow [40].
Epinephrine (a and b-adrenergic, Table 2) in the
treatment of septic shock has been subject to controversy.
Hyperlactatemia during use of epinephrine in sepsis
treatment may be caused by tissue hypoxia, but may also
be explained by direct metabolic effects [32, 41]. Human
data about direct effects of epinephrine on microcircula-
tory perfusion in sepsis are not available, but only in
comparison to NE. In a crossover design, in comparison
to NE plus dobutamine, epinephrine was associated with
lower intestinal pH (pHi) and higher hepatic venous lac-
tate levels under equal systemic hemodynamic conditions
[42], but again interpretation of these data with respect to
splanchnic perfusion is complicated by the intrinsic effect
of epinephrine to cause hyperlactatemia and systemic
acidosis [41, 43].
Phenylephrine (a-adrenergic, Table 2) has been used
to increase MAP in human sepsis from 65 to 75 mmHg
over a 12-h period [34]. Gastric-to-arterial pCO2 differ-
ence, indocyanine clearance, arterial lactate levels and
urine output/creatinine clearance were found to be unal-
tered over time and in comparison to NE, indicating
that intestinal microcirculatory organ perfusion neither
improved nor deteriorated as a result of a phenylephrine-
induced rise in MAP. However, switching from NE to
phenylephrine in patients with septic shock while main-
taining MAP at 70 mmHg at steady-state systemic
hemodynamic variables revealed a rise in pCO2 g-a and a
decrease in ICG clearance and urine output/creatinine
clearance [44]. These indicators of impaired splanchnic
and renal perfusion during phenylephrine infusion disap-
peared after switch-back to NE again.
In cardiopulmonary bypass (CPB)-induced hypoten-
sion, phenylephrine was used to increase MAP from 47
to 68 mmHg [45]. During hypotension, SDF-measured
microcirculatory blood ﬂow of sublingual capillaries was
unchanged in comparison to pre-CPB hypotension, but
after correction with phenylephrine microcirculatory
blood ﬂow was signiﬁcantly reduced. At the same time,
global tissue blood ﬂow (laser Doppler) and spectopho-
tometric microvascular hemoglobin oxygen saturation
(HbiO2) of the tongue increased, underlining the distrib-
utive changes that take place as a result of phenylephrine
administration, not sensed in the absence of direct
observation of the microcirculation. Interestingly, in an
animal model of CPB-induced hypotension, administra-
tion of phenylephrine also reduced tissue perfusion to all
visceral organs despite correction of MAP from 40 to
65 mmHg [46]. However, correction of hypotension by
increasing pump ﬂow improved perfusion of the pancreas,
colon and kidneys.
Vasopressin (Table 3) depletion is believed to play a
causativeroleinsepsis-inducedvasodilatoryshock[47].Ina
mixedpopulationwithcatecholamine-resistantvasodilatory
shock, additional low-dose arginine vasopressin (AVP) was
associated with an increment of pCO2g - aover time, but
lower than NE alone [48]. Direct in vivo observation of the
sublingual microcirculation with OPS imaging in a patient
with non-septic distributive shock revealed marked micro-
circulatory alterations, which did not change after AVP
injection[49].Inarandomizedcontrolledopen-labeltrial in
patients with septic shock, additional use of AVP disclosed
no changes in pCO2g - aand a higher creatinine clearance in
comparison to NE alone [50]. This was in contrast to other
reports of patients with septic shock; both additional con-
tinuous infusion of low dose AVP as well as replacement of
NE by high dose AVP resulted in a signiﬁcant increase of
pCO2g - a[51, 52]. Equally conﬂicting data in animal studies
are suggested to be related to volume status and cardiac
performance [53]. AVP administration in sepsis has been
associated with ischemic skin and tongue lesions in up to
30% [54], although in a recent trial the reported incidence
was considerably lower and not different from norepineph-
rine [55].
In post-CPB cardiac surgery patients with high output
failure, replacement of NE by AVP during steady-state
MAP at 75 mmHg resulted in augmentation of pCO2 g-a
and diminished laser Doppler-measured jejunal mucosal
perfusion, but this was in conjunction with a signiﬁcantly
lower cardiac index [56]. In hemodynamically stable post-
CPB patients, incremental doses of AVP were associated
with a decline in renal blood ﬂow and impairment of the
renal oxygen demand/supply relationship, in the absence
of changes in MAP [57].
Terlipressin (Table 3) not only acts as a long-lasting
prodrug for AVP with a high V1a receptor afﬁnity, but is
also a fast-acting vasopressor peptide per se that evokes
coronary vasoconstriction with reduction in cardiac out-
put [58]. It was originally described as rescue therapy in
catecholamine-resistant septic shock [59]. The dilemma
of its use in septic shock is outlined in a case report in
which a bolus of terlipressin produced signiﬁcantly higher
MAP and urine output while tapering NE doses, but was
also associated with a complete shutdown of sublingual
microcirculatory perfusion and progressive acidosis [60].
More human data of direct effects of terlipressin on
microcirculatory perfusion are not available, but only in
comparison to other (combinations of) vasopressors. In
septic shock after volume resuscitation, there was no
difference between a bolus terlipressin or NE with respect
to lactate levels and creatinine clearance [61]. Additional
terlipressin to NE in septic shock was accompanied by a
rise in bilirubin and aminotransferases [62], but not in
pCO2 g-a [63]. As with AVP, ischemic skin lesions are
reported frequently [64].
With respect to splanchnic perfusion in relation to
terlipressin, it is of note that it has become an established
treatment modality in hepatorenal syndrome and gastro-
intestinal bleeding in liver cirrhosis. This condition is
characterized by a marked vasoconstrictive state in
the liver in combination with systemic vasoplegia. As
2010opposed to septic shock, its potent ability to reduce
splanchnic blood ﬂow has become beneﬁcial under these
conditions, either to increase risk of bleeding or to redi-
rect ﬂow to the kidney [65].
Inotropes
Dobutamine (predominantly b2-adrenergic, Table 4) has
both inotropic and mild vasodilatory effects. In an open-
label setting addition of dobutamine in septic patients was
associated with improved OPS-measured sublingual
microcirculatory perfusion over time, irrespective of
changes in systemic hemodynamic variables [66]. Inter-
estingly, topical application of acetylcholine further
improved microcirculatory perfusion, challenging the
widespread concept of an irresponsive endothelium in
sepsis-induced hypotension. In a crossover setting,
dobutamine attenuated intramucosal acidosis during sep-
sis, whereas dopamine did not change pCO2 g-a under
equal effects in systemic hemodynamics [67]. Addition of
dobutamine to NE in septic patients revealed a lower
pCO2 g-a, but no change in ICG plasma clearance [68, 69];
this could either be due to a direct effect on the micro-
circulation or a result of an increase in cardiac output.
Whether an increase in general splanchnic perfusion
indeed is followed by improved organ function is still a
matter of debate [70].
Dopamine (b2-adrenergic and dopaminergic, Table 4;
in high-dose also a-adrenergic, Table 2) was used in
sepsis for many years in low concentrations for its
potential beneﬁcial effects on renal function as a result
of afferent renal vessel dilatation. However, results of
multiple studies have made such an effect of clinical
relevance very unlikely [71]. Low-dose dopamine in
addition to NE did not alter pHi despite increased overall
splanchnic oxygen consumption [72, 73]. High-dose
dopamine decreased pHi despite a rise in cardiac output,
whereas NE increased pHi at the same MAP [74].
Dopexamine (predominantly dopaminergic, also
b2-adrenergic, Table 4) initially was introduced as an ino-
tropic agent with speciﬁc pro splanchnic perfusion abilities
[75]. However, though dopexamine infusion was associated
with a partial correction of spectrophotometric gastric
HbiO2, pCO2g - aremained unaltered [76]. This might be
compatible with persistence of microcirculatory weak units
Table 3 Vasopressin and analogues (summary of effects in human studies on microvascular perfusion, oxygenation and organ function)
Study [ref] Vasopressor Setting Technique(s) Effects Remarks
[48] AVP Vasodilatory shock,
n = 48
Tonometry Increase in pCO2 g-a and
bilirubin concentrations
over time
Additional to 0.5 mcg/kg/min
norepinephrine,
MAP C70 mmHg;
increase in pCO2 g-a lower
in comparison to
norepinephrine alone
[49] AVP Vasodilatory shock,
n = 1
OPS-imaging No difference in capillary
perfusion
Baseline capillary perfusion
markedly impaired
[50] AVP Vasodilatory shock,
n = 23
Tonometry No change in pCO2 g-a over
time and in comparison to
norepinephrine, no change in
lactate, increase in creatinine
clearance
In comparison to
norepinephrine lower
SOFA score, despite higher
bilirubin
[51, 52] AVP Septic shock,
n = 11, n = 12
Tonometry Increase in pCO2 g-a In addition to norepinephrine
or replacement of
norepinephrine
respectively
[56] AVP Vasodilatory shock,
post cardiac
surgery, n = 8
Tonometry, laser-
Doppler
ﬂowmetry
Decrease in jejuna mucosal
blood ﬂow, increase in
pCO2 g-a
No change in MAP, decrease
in cardiac output
[57] AVP Vasodilatory shock,
post cardiac
surgery, n = 8
Renal vein
thermodilution,
51Cr-EDTA
Decrease in renal blood ﬂow,
increase in glomerular
ﬁltration rate, impairment of
renal oxygen supply/demand
relationship
No change in MAP
[60] Terlipressin Septic shock,
n = 1
OPS-imaging Complete shutdown sublingual
microcirculatory blood ﬂow,
increase in urine output
Rise in MAP from 58 to
105 mmHg
[62, 63] Terlipressin Septic shock,
n = 17, n = 15
Tonometry, laser-
Doppler
ﬂowmetry
Increase of urine output and
creatinine clearance, rise in
bilirubin, no signiﬁcant
change in pCO2 g-a
AVP Argenine vasopressin, OPS orthogonal polarization spectral, pCO2 g-a arterial-to-gastric pCO2 gradient, MAP mean arterial pressure,
EDTA ethylenediaminetetraacetic acid
2011in combination with shunting, not sensed by spectropho-
tometry due to incorporation of arteriolar and venular
hemoglobin. The same dilemma was illustrated in another
study. Dopexamine, in addition to volume loading and
dobutamine, increased ICG-derived splanchnic blood ﬂow,
butwithaconcomitantdecreaseinpHi[77].Apart fromthis
heterogeneity in blood ﬂow between regional circulation
and microcirculation, experimental data also suggested
regionalheterogeneityinbloodﬂowbetweenthegastricand
colon region during the use of dopexamine in sepsis [78].
In postoperative cardiac surgery no difference in
pCO2 g-abetweenlow-dosedopexamineand placebocould
be detected [79]. In another study pHi did not rise despite
an increment in ICG-measured splanchnic blood ﬂow and
cardiac output [80]. Apart from thermogenetic effects of
dopexamine, this might also be explained by a distributive
effect. To date, in postoperative non-cardiac surgery, the
use of dopexamine remains a matter of debate [81, 82].
Levosimendan (calcium sensitizer, Table 4) improves
cardiac contractility and has slight vasodilatory effects.
In patients with sepsis-induced myocardial depression lev-
osimendan in addition to NE plus dobutamine was superior
to an incremental dose of dobutamine, with respect to
pCO2g - a , laser Doppler-measured gastric mucosal perfu-
sion,arteriallactatelevelsandcreatinineclearance,eitheras
a direct effect or as result of improved cardiac output [83].
After abdominal aortic aneurysm surgery pCO2g - awas
lower in the levosimendan group in comparison to placebo,
but despite a higher cardiac output this was not a result of
better regional splanchnic perfusion [84]. In an experi-
mental setting attenuation of sepsis-induced cellular
hypoxia was observed, but simultaneous SDF-imaging
failed to detect changes in microvascular blood ﬂow [85].
Vasodilators
Nitroglycerin (NTG, Table 5) as well as other organic
nitrates undergo intracellular metabolism in order to
produce nitric oxide (NO)-mediated vasodilatation [86].
Table 4 Inotropic agents (summary of effects in human studies on microvascular perfusion, oxygenation and organ function)
Study [ref] Inotrope Setting Technique(s) Effects Remarks
[66] Dobutamine Septic shock, n = 22 OPS-imaging Increase in sublingual
capillary perfusion
over time
Microcirculatory effects
irrespective of systemic
hemodynamics
[67–69] Dobutamine Septic shock, n = 10,
n = 14, n = 12
Tonometry, laser-
Doppler ﬂowmetry,
ICG clearance
Decrease in pCO2 g-a,
increase in gastric
mucosal perfusion, no
change in overall
hepatosplachnic
perfusion
Substantial rise in cardiac
output
[72, 73] Dopamine
(low dose)
Septic shock,
n = 11, n = 16
Tonometry, ICG
clearance
No change in intestinal
pH despite increase in
overall splanchnic
blood ﬂow
Effect on splanchnic
blood ﬂow baseline-
dependent
[76] Dopexamine Septic shock, n = 15 Tonometry,
spectrophotometry
Increase in
microvascular
hemoglobin
saturation, no change
in intestinal pH
These combined
observations suggest
distributive failure
[77] Dopexamine Septic shock, n = 22 Laser-Doppler
ﬂowmetry
Increase in gastric
mucosal blood ﬂow
In addition to
norepinephrine and in
comparison to
epinephrine
[79, 80] Dopexamine Cardiac surgery,
n = 19, n = 14
Tonometry, ICG
clearance
Increase in splanchnic
blood ﬂow and
oxygen consumption,
no change in intestinal
pH
Signiﬁcant rise in cardiac
output
[83] Levosimendan Septic shock, n = 28 Tonometry, laser-
Doppler ﬂowmetry
Decrease in pCO2 g-a
and lactate, increase
in gastric mucosal
perfusion and urine
output
In comparison to
dobutamine
[84] Levosimendan Abdominal aneurysm
repair, n = 20
Tonometry, ICG
clearance
Overall splanchnic
blood ﬂow remained
unaltered, pCO2 g-a
decreased
In comparison to placebo
during aortic clamping,
signiﬁcantly higher
cardiac output
OPS Orthogonal polarization spectral, pCO2g - aarterial-to-gastric pCO2 gradient, ICG indocyanine green
2012Despite the fact that overwhelming NO production is
believed to play an important role in sepsis-induced
hypotension, it has also been suggested as therapeutic
strategy to overcome heterogeneity in microcirculatory
blood ﬂow [5, 87]. This dilemma is illustrated by the fact
that unselective blocking of NO-synthase indeed was
associated with a substantial increase in blood pressure,
but also with a higher mortality [88, 89]. The general idea
that increasing MAP results in a higher net microcircu-
latory perfusion pressure is not in line with physiological
theory of the microcirculation as a low-pressure vascular
compartment [17]. For example, in the brain of healthy
volunteers (with intact autoregulation), NE was unable to
increase estimated cerebral perfusion pressure despite a
rise in MAP, whereas glyceryl trinitrate increased esti-
mated cerebral perfusion pressure as a result of a lower
zero ﬂow pressure, even at a lower MAP [90].
In an uncontrolled setting, NTG was administered to
septic patients who fulﬁlled static systemic hemodynamic
resuscitation endpoints [91]. Despite fulﬁlment of these
endpoints sublingual microcirculatory ﬂow remained
severely impaired. After a single bolus of NTG, instant
improvement of microcirculatory blood ﬂow was
observed, indicating an NO-mediated endothelial ability
for vasodilatation, which based on the analogy of topical
acetylcholine challenged the general idea of endothelial
hyporesponsiveness in sepsis-induced hypotension [66].
However, in a double-blind placebo-controlled setting,
after fulﬁllment of dynamic systemic hemodynamic
resuscitation endpoints, sublingual microcrocirculatory
perfusion improved signiﬁcantly over time, but no effect
of NTG in comparison to placebo could be demonstrated
[92]. In the uncontrolled setting, baseline values for
microvascular blood ﬂow in large vessels was consider-
ably lower in comparison to the controlled setting,
suggesting marked differences in systemic volume status.
In cardiogenic shock, impairment of sublingual
microcirculation has also been observed and associated
with morbidity and mortality [93]. Application of
low-dose NTG in addition to standard care for cardio-
genic shock was associated with a rise in sublingual
perfused capillary density [94]. This was not accompa-
nied by a change in cardiac output or MAP and
disappeared after cessation of NTG administration.
Interestingly, non-pulsatile systemic circulatory ﬂow
support by means of a percutaneous left ventricular assist
device after acute myocardial infarction was also reﬂected
in a better sublingual microcirculatory ﬂow score [95].
In the speciﬁc setting of gastric tube reconstruction,
topical application of NTG improved laser Doppler blood
in the fundus without changes in local HbiO2 [96].
However, no effect was observed during intravenous
NTG in the same setting, suggesting potential interference
with bioactivation [97].
Ketanserin (serotonin 5-HT2 antagonist and weak
a1-adrenergic blocker, Table 5) has been used in the
treatment of hypertension with a reported beneﬁcial effect
on microhemodynamics and hemorheology due vasodi-
latation and inhibition of platelet aggregation [98].
Administration of ketanserin in hypertensive post-CPB
cardiac surgery patients effectively lowered MAP, while
sublingual capillary blood ﬂow was preserved [99].
Table 5 Vasodilators (summary of effects in human studies on microvascular perfusion, oxygenation and organ function)
Study [ref] Inotrope Setting Technique(s) Effects Remarks
[91] Nitroglycerin Septic shock,
n = 8
OPS-imaging Instantaneous increase in
sublingual
microcirculatory blood
ﬂow after a 0.5 mg iv bolus
Open label, after fulﬁlment of
static pressure resuscitation
endpoint
[92] Nitroglycerin Septic shock,
n = 70
SDF-imaging No difference in sublingual
microcirculatory blood
ﬂow after 24 h
Placebo controlled double-
blind, after fulﬁlment of
dynamic resuscitation
endpoints.
[94] Nitroglycerin Cardiogenic shock,
n = 20
SDF-imaging Increase in sublingual
perfused capillary density
Effect ceased after stop
medication
[99] Ketanserin Cardiac surgery,
n = 6
SDF-imaging No change in sublingual
perfused capillary density
and microvascular blood
ﬂow
MAP dropped from 86 to
68 mmHg
[102] Prostacyclin Septic shock,
n = 16
Tonometry Increase in gastric
mucosal pH
Intravenous prostacyclin
[103] Prostacyclin Septic shock,
n = 16
Tonometry,
ICG clearance
Decrease in pCO2 g-a,n o
change in overall
splanchnic perfusion
Patients with septic shock
and pulmonary
hypertension, aerosolized
prostacyclin; effects in
comparison to baseline and
inhaled nitric oxyde
OPS Orthogonal polarization spectral, SDF sidestream dark ﬁeld, pCO2 g-a arterial-to-gastric pCO2 gradient, ICG indocyanine green,
MAP mean arterial pressure
2013Prostacyclin (cyclic adenosine monophosphate acti-
vator, Table 5) was initially propagated as a drug for
improvement of oxygen extraction deﬁcits, suspected to
cause tissue dysoxia [100]. Since then it has been studied
extensively, especially in experimental settings, for its
potential beneﬁcial effect on organ perfusion, as it plays a
crucial role in the physiological endothelial vasodilatory
response to ischemia/reperfusion [101]. Administration of
intravenous prostacyclin after conventional resuscitation
was associated with higher pHi and indicative for out-
come [102]. Similar effects on pHi were reported during
aerosolized prostacyclin despite unaltered ICG clearance
in patients with pulmonary hypertension [103].
During CPB, infusion of prostacyclin blunted jejunal
vasomotion, resulting in a reduced ability to maintain
laser Doppler-measured jejunal perfusion constant under
variation of blood pressure (autoregulation) [104]. On the
other hand, jejunal perfusion increased signiﬁcantly in
parallel to a drop in MAP, but unfortunately pCO2 g-a was
not measured to establish the overall effect on jejunal
microcirculatory perfusion.
Conclusions
Regardless of practical limitations, there is a growing
perception that shock should be deﬁned at the level of the
microcirculation. Previous clinical research was limited to
surrogate markers of organ microcirculatory blood per-
fusion such as tonometry, laser Doppler ﬂowmetry and
ICG clearance. Recent developments have brought direct
in vivo observation of the microcirculation in critically ill
patients within reach, albeit limited to accessible organs.
To date there are no data available in support of the idea
that increasing MAP is beneﬁcial from the perspective of
microcirculatory perfusion and/or oxygenation, and such
an idea is not in line with the physiological theory of the
microcirculation as a low-pressure vascular compartment.
In septic shock several reports have demonstrated an
absence of effect on microcirculatory perfusion above a
MAP of 65 mmHg, but a lower threshold has not been
established. The role of vasodilators in sepsis as a thera-
peutic strategy to recruit ‘microcirculatory weak units’ is
yet to be elucidated. In cardiogenic shock neither vaso-
pressors nor inotropic agents have been proven beneﬁcial
in terms of organ perfusion, but increasing systemic ﬂow
by means of several assist devices are now associated
with better microcirculatory ﬂow.
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